Akt - RSK - S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

Science Signaling

Volumn 3, Issue 136, 2010, Pages

  Moritz, Albrecht ^a   Li, Yu ^a   Guo, Ailan ^a   Villén, Judit ^b,d   Wang, Yi ^a   MacNeill, Joan ^a   Kornhauser, Jon ^a   Sprott, Kam ^a   Zhou, Jing ^a   Possemato, Anthony ^a   Ren, Jian Min ^a   Hornbeck, Peter ^a   Cantley, Lewis C ^b,c   Gygi, Steven P ^b   Rush, John ^a   Comb, Michael J ^a  

^a CELL SIGNALING TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN; S6 KINASE; SCATTER FACTOR RECEPTOR; SERINE; SMALL GLUTAMINE RICH TETRATRICOPEPTIDE REPEAT CONTAINING PROTEIN ALPHA; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; CARRIER PROTEINS; CELL LINE; HUMANS; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SUBSTRATE SPECIFICITY; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 77956621143     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2000998     Document Type: Article

References (32)

1. A. F. Gazdar, J. D. Minna, Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops. Cancer Prev. Res. 1, 156-160 (2008).
2. S. V. Sharma, D. W. Bell, J. Settleman, D. A. Haber, Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181 (2007).
3. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57-70 (2000).
4. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
5. I. B. Weinstein, Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
6. A. Friedman, N. Perrimon, A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. Nature 444, 230-234 (2006).
7. R. Anjum, J. Blenis, The RSK family of kinases: Emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747-758 (2008).
8. K. G. Bache, T. Slagsvold, H. Stenmark, Defective downregulation of receptor tyrosine kinases in cancer. EMBO J. 23, 2707-2712 (2004).
9. P. Blume-Jensen, T. Hunter, Oncogenic kinase signalling. Nature 411, 355-365 (2001).
10. T. L. Yuan, L. C. Cantley, PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27, 5497-5510 (2008).
11. B. D. Manning, L. C. Cantley, AKT/PKB signaling: Navigating downstream. Cell 129, 1261-1274 (2007).
12. J. E. Syka, J. J. Coon, M. J. Schroeder, J. Shabanowitz, D. F. Hunt, Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 101, 9528-9533 (2004).
13. H. Zhang, X. Zha, Y. Tan, P. V. Hornbeck, A. J. Mastrangelo, D. R. Alessi, R. D. Polakiewicz, M. J. Comb, Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J. Biol. Chem. 277, 39379-39387 (2002).
14. A. Leitner, A. Foettinger, W. Lindner, Improving fragmentation of poorly fragmenting peptides and phosphopeptides during collision-induced dissociation by malondialdehyde modification of arginine residues. J. Mass Spectrom. 42, 950-959 (2007).
15. A. M. Palumbo, J. J. Tepe, G. E. Reid, Mechanistic insights into the multistage gas-phase fragmentation behavior of phosphoserine- and phosphothreonine-containing peptides. J. Proteome Res. 7, 771-779 (2008).
16. D. L. Swaney, G. C. McAlister, J. J. Coon, Decision tree - driven tandem mass spectrometry for shotgun proteomics. Nat. Methods 5, 959-964 (2008).
17. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, H. Haack, J. Nardone, K. Lee, C. Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J. M. Ren, J. Yuan, C. E. Bakalarski, J. Villén, J. M. Kornhauser, B. Smith, D. Li, X. Zhou, S. P. Gygi, T. L. Gu, R. D. Polakiewicz, J. Rush, M. J. Comb, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
18. A. Guo, J. Villén, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, Y. Wang, J. MacNeill, J. Mitchell, S. P. Gygi, J. Rush, R. D. Polakiewicz, M. J. Comb, Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U.S.A. 105, 692-697 (2008).
19. G. A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, W. J. Kim, R. A. Okimoto, D. W. Bell, D. C. Sgroi, J. G. Christensen, J. Settleman, D. A. Haber, Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. U.S.A. 103, 2316-2321 (2006).
20. T. J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
21. P. V. Hornbeck, I. Chabra, J. M. Kornhauser, E. Skrzypek, B. Zhang, PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4, 1551-1561 (2004).
22. C. E. Bakalarski, J. E. Elias, J. Villén, W. Haas, S. A. Gerber, P. A. Everley, S. P. Gygi, The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J. Proteome Res. 7, 4756-4765 (2008).
23. S. E. Ong, B. Blagoev, I. Kratchmarova, D. B. Kristensen, H. Steen, A. Pandey, M. Mann, Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
24. J. V. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar, P. Mortensen, M. Mann, Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648 (2006).
25. 2/M involves cyclin B1/Cdk1. J. Biol. Chem. 282, 15965-15972 (2007).
26. S. Dupont, A. Mamidi, M. Cordenonsi, M. Montagner, L. Zacchigna, M. Adorno, G. Martello, M. J. Stinchfield, S. Soligo, L. Morsut, M. Inui, S. Moro, N. Modena, F. Argenton, S. J. Newfeld, S. Piccolo, FAM/USP9x, a deubiquitinating enzyme essential for TGFβ signaling, controls Smad4 monoubiquitination. Cell 136, 123-135 (2009).
27. F. Tremblay, S. Brûlé, S. Hee Um, Y. Li, K. Masuda, M. Roden, X. J. Sun, M. Krebs, R. D. Polakiewicz, G. Thomas, A. Marette, Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 104, 14056-14061 (2007).
28. L. Whitesell, S. L. Lindquist, HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761-772 (2005).
29. G. Buchanan, C. Ricciardelli, J. M. Harris, J. Prescott, Z. C. Yu, L. Jia, L. M. Butler, V. R.Marshall, H. I. Scher, W. L. Gerald, G. A. Coetzee, W. D. Tilley, Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein a. Cancer Res. 67, 10087-10096 (2007).
30. J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Jänne, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
31. J. Rush, A. Moritz, K. A. Lee, A. Guo, V. L. Goss, E. J. Spek, H. Zhang, X. M. Zha, R. D. Polakiewicz, M. J. Comb, Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23, 94-101 (2005).
32. Acknowledgments: We thank other members of Cell Signaling Technology Inc. (CST) for help and fruitful discussions, especially R. Polakiewicz, T.-L. Gu, and K. Rikova. We thank C. Hoffman, R. Poor, K. Anderson, and D. Comb for graphic assistance. Funding: NIH grant K99CA 140789 to J.V. Author contributions: A.M., Y.L., A.G., and J.V. performed the experiments and analyzed the data. J.M., K.S., J.Z., A.P., and J.M.R. performed the experiments. Y.W., J.K., and P.H. performed bioinformatics analysis; L.C.C., S.P.G., and J.R. designed the experiments and analyzed the data; M.J.C. designed the experiments, analyzed the data, and wrote the paper. Competing interests: CST has submitted a patent application for a number of novel sites identified in this study. The claims relate to the new sites, reagents (including antibodies) specific thereto, and are intended solely to protect CST's future ability to sell such reagents. L.C.C. is a paid member of the scientific advisory board of CST. M.J.C. is president and CEO of CST. Accession numbers: Phosphoproteomics data have been deposited with the PhosphoSitePlus protein modification database (http://ms.phosphosite.org:5080/).